High incidence of intracranial haemorrhage in Egyptian children with congenital afibrinogenaemia

被引:3
作者
Abdelwahab, Magy [1 ]
de Moerloose, Philippe [2 ]
Casini, A. [2 ,3 ]
机构
[1] Cairo Univ, Kasralainy Hosp, Paediat & Paediat Haematol Dept, Social & Prevent Med,Paediat Hosp, Cairo, Egypt
[2] Univ Geneva, Fac Med, Geneva, Switzerland
[3] Univ Hosp Geneva, Div Angiol & Haemostasis, Geneva, Switzerland
关键词
afibrinogenaemia; epidural haemorrhage; intraparenchymal haemorrhage; subarachnoid haemorrhage; subdural haemorrhage; FIBRINOGEN; IDENTIFICATION; DEFICIENCIES; MANAGEMENT; DISORDERS; REGISTRY;
D O I
10.1111/hae.14738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionIntracerebral hemorrhage (ICH) is associated with high morbidity and mortality in patients with congenital afibrinogenaemia. Details on location of cerebral haemorrhage, management and neurological outcomes are lacking. MethodsWe performed a retrospective study on Egyptian children with congenital afibrinogenaemia who experienced ICH, in order to estimate frequency, symptoms and neurological outcomes. ResultsAmong 58 children with congenital afibrinogenaemia treated on demand, 18 (31%) had an history of ICH (28 episodes). The first ICH occurred at a median age of 1 year (Q1-Q3 1-7 years). Impaired consciousness level, vomiting and seizures were the most common presenting symptoms. Spontaneous bleeding was associated with a more severe clinical presentation and worse neurological outcomes, including hydrocephaly and impaired cognitive development. Only half of ICH events (n = 14) were treated in less than 24 h from the onset of symptoms. Fibrinogen replacement by Fresh Frozen Plasma (FFP), cryoprecipitate or fibrinogen concentrates was administered in seven (25%), 19 (68%) and three (10%) ICH events, respectively. Overall, seven (25%) ICH occurring in four patients required a surgical intervention. After the ICH, six patients started secondary prophylaxis. The cumulative incidence of ICH at 10 years was 35% (95% CI 23-51) and at 20 years was 40% (95 CI% 26.7-58.8). ConclusionIn our cohort of children with congenital afibrinogenaemia, ICH was very frequent and associated with adverse neurological outcomes and death. Further studies are required to determine whether primary prophylaxis starting early in childhood is indicated after diagnosis.
引用
收藏
页码:572 / 577
页数:6
相关论文
共 24 条
[1]   Rare coagulation disorders: a study of 70 cases in the Egyptian population [J].
Abdelwahab, M. ;
Khaddah, N. .
HAEMOPHILIA, 2012, 18 (05) :E386-E388
[2]   Rare bleeding disorder registry: Deficiencies of factors II, V, VII, X, XIII fibrinogen and dysfibrinogenemias [J].
Acharya, SS ;
Coughlin, A ;
DiMichele, DM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (02) :248-256
[3]   Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency [J].
Asselta, Rosanna ;
Plate, Manuela ;
Robusto, Michela ;
Borhany, Munira ;
Guella, Ilaria ;
Solda, Giulia ;
Afrasiabi, Abdolreza ;
Menegatti, Marzia ;
Shamsi, Tahir ;
Peyvandi, Flora ;
Duga, Stefano .
THROMBOSIS AND HAEMOSTASIS, 2015, 113 (03) :567-576
[4]   Fibrinogen replacement therapy for congenital fibrinogen deficiency [J].
Bornikova, L. ;
Peyvandi, F. ;
Allen, G. ;
Bernstein, J. ;
Manco-Johnson, M. J. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (09) :1687-1704
[5]   Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH [J].
Casini, A. ;
Undas, A. ;
Palla, R. ;
Thachil, J. ;
De Moerloose, P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (09) :1887-1890
[6]   Management of congenital quantitative fibrinogen disorders: a Delphi consensus [J].
Casini, A. ;
de Moerloose, P. .
HAEMOPHILIA, 2016, 22 (06) :898-905
[7]   FGB mutations leading to congenital quantitative fibrinogen deficiencies: An update and report of four novel mutations [J].
Casini, A. ;
Lukowski, S. ;
Quintard, V. Louvain ;
Crutu, A. ;
Zak, M. ;
Regazzoni, S. ;
de Moerloose, P. ;
Neerman-Arbez, M. .
THROMBOSIS RESEARCH, 2014, 133 (05) :868-874
[8]   Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management [J].
Casini, Alessandro ;
Neerman-Arbez, Marguerite ;
de Moerloose, Philippe .
BLOOD REVIEWS, 2021, 48
[9]   Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia [J].
Casini, Alessandro ;
von Mackensen, Sylvia ;
Santoro, Cristina ;
Khayat, Claudia Djambas ;
Belhani, Meriem ;
Ross, Cecil ;
Dorgalaleh, Akbar ;
Naz, Arshi ;
Unal, Ekrem ;
Abdelwahab, Magy ;
Lozeron, Elise Dupuis ;
Trillot, Nathalie ;
Susen, Sophie ;
Peyvandi, Flora ;
de Moerloose, Philippe .
BLOOD, 2021, 137 (22) :3127-3136
[10]   The burden and management of FXIII deficiency [J].
de Jager, T. ;
Pericleous, L. ;
Kokot-Kierepa, M. ;
Naderi, M. ;
Karimi, M. .
HAEMOPHILIA, 2014, 20 (06) :733-740